Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
about
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatmentPilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLCClinical significance of post-progression survival in lung cancer
P2860
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Post-progression survival in p ...... uired resistance to gefitinib.
@en
Post-progression survival in p ...... uired resistance to gefitinib.
@nl
type
label
Post-progression survival in p ...... uired resistance to gefitinib.
@en
Post-progression survival in p ...... uired resistance to gefitinib.
@nl
prefLabel
Post-progression survival in p ...... uired resistance to gefitinib.
@en
Post-progression survival in p ...... uired resistance to gefitinib.
@nl
P2093
P2860
P1476
Post-progression survival in p ...... uired resistance to gefitinib.
@en
P2093
Geon Kook Lee
Heung Tae Kim
Hyojeong Kim
Ji-Youn Han
Young Joo Lee
P2860
P304
P356
10.3346/JKMS.2013.28.11.1595
P577
2013-10-31T00:00:00Z